Clinicopathological comparison of triple negative breast cancers with non-triple negative breast cancers in a hospital in North India

Nabi, MG; Ahangar, Andleeb; Wahid, M.I.A.; Kuchay, Sanaullah

doi:10.4103/1119-3077.153248

Cited by 28 publications

(22 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study is the largest study from India to date that subcategorizes breast cancers into three groups – HR+, HER2+, and TNBC. There are several studies from the Indian subcontinent regarding either HR positivity alone or HR+[ 4 8 9 18 ] and TNBCs[ 19 20 21 22 ] with only six studies delineating HER2-positive and HR-negative status as a separate category. [ 7 10 11 21 22 23 24 ] Of the latter, only one has a relatively comparable volume of 2001 cases,[ 7 ] with 16% of HER2-positive cases which is similar to the 15% found in the present study.…”

Section: Discussionmentioning

confidence: 99%

Estrogen receptor, Progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: A retrospective study of 5436 women from a regional cancer center in South India

Kumar

Panwar

Adiga

et al. 2018

South Asian J Cancer

View full text Add to dashboard Cite

Aim:The aim of the study was to analyze the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status over 7 years in South Indian women with breast cancer. Further analysis of a subgroup was done to study clinically defined subtypes and the role of preanalytical factors in needle core biopsies (NCBs) and excised specimens.Materials and Methods:This was a retrospective study from January 2010 to December 2016. Patients diagnosed with invasive breast cancer and available immunohistochemistry (IHC) reports of ER, PR, and HER2 status were analyzed. The cases for the year 2016 were analyzed further to observe the impact of preanalytical factors on the IHC staining patterns and surrogate status.Results:A total of 5436 patients were included with a median age of 48 years. Among these, 65% were ≤ 55 years. The overall incidence of hormone receptor (HR)-positive patients was 48%; HER2 positive, 15%; and triple-negative breast cancer (TNBC), 37%. The incidence of HR positive, HER2 positive, and TNBC were 45%, 16%, and 39% and 53%, 13%, and 34% in patients <56 years and over 55 years, respectively (P < 0.001). There was an increase in HR positivity and decrease in TNBCs over time. There was no significant difference in the staining patterns in NCBs and excised specimens.Conclusion:With time, there is an increase in hormone-positive tumors which may be attributed to better IHC techniques and tissue handling. There was no statistical difference in the patterns of ER, PR, and HER2 immunostaining in core biopsy and excised specimens.

show abstract

Section: Discussionmentioning

confidence: 99%

Estrogen receptor, Progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: A retrospective study of 5436 women from a regional cancer center in South India

Kumar

Panwar

Adiga

et al. 2018

South Asian J Cancer

View full text Add to dashboard Cite

show abstract

“…Seventeen cross-sectional studies that involving 7,237 patients with breast cancer were included in this review (Table 1). [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] Mean age of patients ranged from 43 to 55 years across studies, with a weighted average of age 50 years. Proportion of patients who were premenopausal ranged from 27% to 67% across studies, with a weighted average of 41%.…”

Section: Study Characteristicsmentioning

confidence: 99%

Prevalence of triple negative breast cancer in India – systematic review and meta analysis.

Sandhu

Erqou

Patterson

et al. 2016

JCO

View full text Add to dashboard Cite

Purpose There is considerable variation in prevalence rates of triple-negative breast cancer (TNBC) reported by various studies from India. We performed a systematic review and literature-based metaanalysis of these studies. Methods We searched databases of Medline, Scopus, EMBASE, and Web of Science for studies that reported on the prevalence of TNBC in India that were published between January 1, 1999, and December 31, 2015. We extracted relevant information from each study by using a standardized form. We pooled study-specific estimates by using random-effects meta-analysis to provide summary estimates. We explored sources of heterogeneity by using subgroup analyses and metaregression. Results Data were obtained from 17 studies that involved 7,237 patients with breast cancer. Overall combined prevalence of TNBC was 31% (95% CI, 27% to 35%). There was substantial heterogeneity across the studies (I 2 of 91% [95% CI, 88% to 94%]; P < .001) that was not explained by available study level characteristics, including study location, definition of human epidermal growth factor receptor 2 or estrogen receptor, mean age of participants, proportion of patients with premenopausal cancer, grade 3 disease, or tumor size > 5 cm. Overall combined prevalence of hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer was 48% (95% CI, 42% to 54%) and 27% (95% CI, 24% to 31%), respectively. There was no evidence of publication bias. Conclusion Prevalence of TNBC in India is considerably higher compared with that seen in Western populations. As many as as one in three women with breast cancer could have triple-negative disease. This finding has significant clinical relevance as it may contribute to poor outcomes in patients with breast cancer in India. Additional research is needed to understand the determinants of TNBC in India.

show abstract

“…Traditionally, there have been several widely accepted methods for clinical classification of types of breast cancer. These include classification based on: (i) histology using morphological characteristics; (ii) immunohistochemical (IHC) markers, also used here to guide data analysis; and (iii) more recently, using gene expression profiles as the standard [ 8 , 10 , 35 ]. The significance of our investigation is that these traditional protocols could be complemented by the results in this investigation.…”

Section: Discussionmentioning

confidence: 99%

“…Integrating somatic, epigenomic and gene expression data with traditional protocols holds promise not only for defining the types of breast cancer, but also for causally associating such types with the molecular mechanisms driving and distinguishing them. Moreover, integrating omics with standard protocols may help to eliminate errors associated with traditional protocols, such as IHC [ 8 , 10 ] and improve patient classification.…”

Section: Discussionmentioning

confidence: 99%

“…Most notably, unlike non-TNBC, currently there are no effective targeted therapies for TNBC, cytotoxic chemotherapy remains the only effective therapeutic modality [ 2 , 3 ]. Accumulating evidence from both epidemiologic and clinical studies has revealed that TNBC has worse outcomes and survival rates than non-TNBC [ 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 ]. However, the molecular mechanisms underlying the etiological and biological differences between the two types of breast cancer have not been well characterized.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer

Mamidi

Zhang

et al. 2020

Cancers

View full text Add to dashboard Cite

Background: The recent surge of next generation sequencing of breast cancer genomes has enabled development of comprehensive catalogues of somatic mutations and expanded the molecular classification of subtypes of breast cancer. However, somatic mutations and gene expression data have not been leveraged and integrated with epigenomic data to unravel the genomic-epigenomic interaction landscape of triple negative breast cancer (TNBC) and non-triple negative breast cancer (non-TNBC). Methods: We performed integrative data analysis combining somatic mutation, epigenomic and gene expression data from The Cancer Genome Atlas (TCGA) to unravel the possible oncogenic interactions between genomic and epigenomic variation in TNBC and non-TNBC. We hypothesized that within breast cancers, there are differences in somatic mutation, DNA methylation and gene expression signatures between TNBC and non-TNBC. We further hypothesized that genomic and epigenomic alterations affect gene regulatory networks and signaling pathways driving the two types of breast cancer. Results: The investigation revealed somatic mutated, epigenomic and gene expression signatures unique to TNBC and non-TNBC and signatures distinguishing the two types of breast cancer. In addition, the investigation revealed molecular networks and signaling pathways enriched for somatic mutations and epigenomic changes unique to each type of breast cancer. The most significant pathways for TNBC were: retinal biosynthesis, BAG2, LXR/RXR, EIF2 and P2Y purigenic receptor signaling pathways. The most significant pathways for non-TNBC were: UVB-induced MAPK, PCP, Apelin endothelial, Endoplasmatic reticulum stress and mechanisms of viral exit from host signaling Pathways. Conclusion: The investigation revealed integrated genomic, epigenomic and gene expression signatures and signing pathways unique to TNBC and non-TNBC, and a gene signature distinguishing the two types of breast cancer. The study demonstrates that integrative analysis of multi-omics data is a powerful approach for unravelling the genomic-epigenomic interaction landscape in TNBC and non-TNBC.

show abstract

Clinicopathological comparison of triple negative breast cancers with non-triple negative breast cancers in a hospital in North India

Abstract: Triple negative breast cancer represented 34.4% which is higher than the range normally reported in the literature. TNBC are associated with younger age, large tumor size, high-grade tumors, and a higher rate of axillary lymph node metastasis.

Cited by 28 publications

References 12 publications

Estrogen receptor, Progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: A retrospective study of 5436 women from a regional cancer center in South India

Estrogen receptor, Progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: A retrospective study of 5436 women from a regional cancer center in South India

Prevalence of triple negative breast cancer in India – systematic review and meta analysis.

Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer

Contact Info

Product

Resources

About